Generation of conditional ALK F1174L mutant mouse models for the study of neuroblastoma pathogenesis

Area of Science:

• Oncology
• Genetics
• Developmental Biology

Background:

• Neuroblastoma is a challenging pediatric cancer with unclear pathogenesis despite known genetic alterations.
• Somatic mutations in the anaplastic lymphoma kinase (ALK) gene, such as ALK F1174L, are frequently found in neuroblastoma.
• ALK F1174L mutations are often associated with MYCN gene amplification, a marker of poor prognosis.

Purpose of the Study:

• To investigate the role of ALK F1174L in neuroblastoma development.
• To determine if ALK F1174L alone or in combination with MYCN can induce neuroblastoma in vivo.
• To establish a conditional mouse model for studying neuroblastoma pathogenesis.

Main Methods:

• Engineered a mouse model with a conditional, endogenous promoter-driven Alk locus for ALK F1174L expression.
• Utilized a Cre-loxP system for spatiotemporal control of ALK F1174L induction.
• Co-expressed ALK F1174L and MYCN in mice to assess tumor development.

Main Results:

• Expression of ALK F1174L alone enhanced sympathetic progenitor proliferation and ganglia size but did not cause neuroblastoma.
• Co-expression of ALK F1174L and MYCN frequently led to lethal neuroblastoma, even in a MYCN-tolerant genetic background.
• Physiological ALK F1174L expression significantly potentiated MYCN's oncogenic activity in vivo.

Conclusions:

• ALK F1174L acts as a potent co-oncogene with MYCN in neuroblastoma pathogenesis.
• Conditional mouse models expressing ALK F1174L and MYCN are valuable for studying neuroblastoma.
• These findings provide insights into the molecular mechanisms driving intractable pediatric cancers.